Three new updates on GLP-1 medications came in this week, and they show how much testing still stands between the drugs in development and your pharmacy shelf. The updates cover a wide age range, from teenagers to adults with heart and kidney conditions, and two different drugs from the same manufacturer. None of these trials change what is available to patients right now. If you are watching this category for future options, these developments are worth understanding, but they are not something to act on yet.
Retatrutide, Eli Lilly's experimental obesity drug, remains in a large Phase 3 trial studying its effects on heart and kidney outcomes in adults with obesity. That trial, known as TRIUMPH-Outcomes, is active but not recruiting new participants, and it is not expected to finish until 2029. This kind of trial takes years because researchers need to track cardiovascular and kidney events over time, not just short-term weight changes. Until the study completes and the results go through FDA review, retatrutide stays in testing and is not available to the public.
Eli Lilly has also opened recruitment for a Phase 3 trial of orforglipron, its pill-form GLP-1 medication, aimed at kids and teens with obesity or overweight. This pediatric trial is structured as a platform trial, meaning it can evaluate multiple treatment approaches for younger patients within a single study framework. Recruiting children and teens for a Phase 3 trial signals that Lilly is preparing the evidence base needed for a possible pediatric indication down the road, but that process still requires the trial to finish and the data to be reviewed before any approval decision follows.
Separately, Lilly has started a large trial of orforglipron in adults with atherosclerotic cardiovascular disease or chronic kidney disease, called ATTAIN-Outcomes. This study is currently recruiting participants and will look at how the pill-form GLP-1 affects cardiovascular outcomes in people who already have heart or kidney conditions. Because orforglipron is taken as a pill rather than an injection, a positive result here could matter for patients who prefer or need an oral option. That said, the drug is not approved or available to the public yet, and this trial adds another layer of testing before that can change.
If you are tracking these medications because you or someone you know may benefit from them, the practical takeaway is patience paired with attention to what is actually approved today. These trials tell you where the research is headed, not what you can access right now. I would suggest checking back periodically for updates on trial completion dates and FDA decisions, and talking with your doctor about what options currently exist for your situation. Two things remain true at once: the pipeline for GLP-1 medications keeps expanding, and none of that expansion changes the choices available to patients this year.
Key details
Retatrutide remains in testing, with a major heart and kidney trial not finishing until…
Eli Lilly is now recruiting kids and teens with obesity for a Phase 3 trial of its…
Eli Lilly has started a large heart disease trial for its pill-form GLP-1, still…
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-08-28